Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target

Abstract

The discovery of ligands via affinity-mediated selection of DNA-encoded chemical libraries is driven by the quality and concentration of the protein target. G-protein-coupled receptors (GPCRs) and other membrane-bound targets can be difficult to isolate in their functional state and at high concentrations, and therefore have been challenging for affinity-mediated selection. Here, we report a successful selection campaign against protease-activated receptor 2 (PAR2). Using a thermo-stabilized mutant of PAR2, we conducted affinity selection using our >100-billion-compound DNA-encoded library. We observed a number of putative ligands enriched upon selection, and subsequent cellular profiling revealed these ligands to comprise both agonists and antagonists. The agonist series shared structural similarity with known agonists. The antagonists were shown to bind in a novel allosteric binding site on the PAR2 protein. This report serves to demonstrate that cell-free affinity selection against GPCRs can be achieved with mutant stabilized protein targets.

Keywords

medicinal organic synthetic combinatorial G-protein-coupled receptor (GPCR)ligand binding receptor binding cell-based assays

Introduction

The protease-activated receptors (PARs) are a class of G-protein-coupled receptors (GPCRs) that are activated by extracellular proteases.^1–3 Proteolytic cleavage near the receptor N-terminus reveals a stimulatory sequence that can bind the receptor in an intramolecular fashion and induce signaling. Four members of the PAR family have been described (PAR1–4), and some of these have attracted interest as therapeutic targets. PAR1, for instance, is antagonized by the anticlotting drug Vorapaxar.⁴

PAR2 is expressed in a variety of vascular and smooth muscle tissues, including in the gastrointestinal tract, the lung, and the skin. Proteolytic activation of PAR2 unmasks the peptide sequence SLIGKV, which then binds and induces inflammatory signaling cascades. Antagonists to PAR2 signaling could have potential application in inflammation, pain, and other diseases. Despite the therapeutic potential of such agents, relatively few PAR2 antagonists have been described.^5,6 Several authors of this report previously reported the cocrystal structures of several PAR2 antagonists bound to the receptor.⁷ The discovery of one of these antagonists via affinity-mediated selection of DNA-encoded chemical libraries (DECLs)^8–10 is described here.

GPCRs are membrane-spanning proteins that have traditionally been difficult to isolate in a soluble, nonaggregated, and correctly folded form. Because the affinity selection of DECLs typically requires the use of highly pure and soluble protein targets, GPCRs pose obvious challenges. Several recent reports have described approaches to overcoming these challenges ( Fig. 1 ). In a model study,¹¹ the β2 adrenergic receptor was expressed in insect cells and extracted and purified in detergent-containing buffers. The receptor was the wild-type sequence with the exception of an N-terminal FLAG tag and point mutation of a glycosylation site. This detergent-solubilized receptor was loaded onto anti-FLAG beads and used for affinity-mediated selection with DECLs; a novel antagonist with an IC₅₀ of 1.9 µM was discovered. Cooperative binding with an orthosteric ligand revealed this compound to be an allosteric antagonist.

Figure 1.

Comparison of methods for displaying GPCRs for DEL selection. (a) Detergent solubilization and display on beads.⁷ (b) Overexpression on cells and exposure to library.⁸ (c) Mutational stabilization and display on beads (current work).

Whole cells have also been reported to be an effective means to present high-quality, high-concentration proteins to DECLs. In a seminal report,¹² workers at GSK described their efforts to discover antagonists of NK3, a GPCR of the tachykinin family. Rather than purify the receptor, they expressed it at high levels in HEK293 cells using a BacMam viral vector. Cells transduced with virus without the NK3 gene were used as negative controls. Affinity-mediated selection was conducted directly on the cells, and several families of antagonists were discovered, with potencies down to single-digit nanomolar. It should be noted that the expression levels of NK3 were high (500,000 copies/cell). High expression levels in this system are presumably needed to mimic the high concentrations of purified soluble proteins required for conventional affinity-mediated selection experiments.

For our efforts with PAR2, we turned to a third approach: mutational stabilization.^7,13 Thermostabilized GPCRs (StaRs) have found utility in structural studies of GPCRs^14–16 and in GPCR lead and fragment-based discovery.^17,18 StaRs are generated by iterative point mutations and exhibit increased stability relative to wild-type receptors while retaining their ability to bind to known ligands. StaRs can be stabilized in particular conformations and activation states depending on whether agonist or antagonist binding is maintained through the mutational stabilization process. The utility of StaRs is evidenced by the growing number of GPCR x-ray structures obtained using StaR constructs.

In our PAR2 campaign, we wished to determine not only which library compounds bound to PAR2, but also their binding sites and competitive behavior. In order to derive this information, an affinity-mediated selection campaign was designed in which binders were identified by incubation with the target in the absence of any ligands, and parallel selections were also undertaken in which binding sites were fully occupied using known ligands as competitors. Competition is often used in DECL affinity selection to classify library members on the basis of their competitiveness, and to form hypotheses around binding site and modulatory function. Examples include the use of dasatinib to probe the ATP site of BTK,¹⁹ SB-235375 to identify NK3 antagonists,¹² and ZSTK474 to identify ATP-competitive ligands for PI3Kα.²⁰ Use of competitors in biophysical screening is not limited to DECL selection; affinity selection–mass spectrometry (AS-MS) screens routinely utilize competitors to characterize binding sites of hits,²¹ including when screening GPCRs such as the M₂ acetylcholine receptor.²²

Materials and Methods

Small-Molecule Pull-Down by Immobilized PAR2

PAR2 (final concentration 5 µM) and a small molecule (AZ8838 or AZ7188, final concentration 5 µM) were incubated in selection buffer (50 mM HEPES, 150 mM NaCl, 0.004% lauryl maltose neopentyl glycol, 0.002% cholesteryl hemisuccinate, 0.02% DMSO, 1 mg/mL sheared salmon sperm DNA, pH 7.4) in a total volume of 60 µL for 1 h at room temperature. Protein immobilization was then conducted using a 5 µL bed of nickel affinity matrix (His-Select High-Flow Nickel Affinity Gel; Phynexus, San Jose, CA) and 20 passages followed by three washes with 200 µL of incubation buffer aliquots. Elution was performed by heating the matrix to 95 °C in the presence of NuPAGE LDS sample buffer (Thermo Fisher, Waltham, MA). Protein capture was assessed using denaturing polyacrylamide gel electrophoresis (PAGE) for the input, flow-through, and elution. Relative concentrations of small molecule were assessed for the input, flow-through, and washes using liquid chromatography–mass spectrometry (LCMS). No-protein control and off-target capture assays were also run for comparative purposes.

Affinity-Mediated Selection of DECLs

This campaign comprised seven parallel selection conditions in which 10 nmol of a mix of 20 different DECLs was diluted into selection buffer (50 mM HEPES, 150 mM NaCl, 0.004% lauryl maltose neopentyl glycol, 0.002% cholesteryl hemisuccinate, 0.02% DMSO, 1 mg/mL sheared salmon sperm DNA, pH 7.4) and incubated with no protein or 5 µM PAR2 supplied either precomplexed or in the apo form. For the selections conducted with PAR2 supplied in the apo form, library mix and competitors, where included, were incubated together in solution in a 60 µL volume for 1 h at room temperature prior to capture on a 5 µL bed of nickel affinity matrix (His-Select High-Flow Nickel Affinity Gel) by 20 passages, followed by eight washes with 200 µL of incubation buffer aliquots. For the selections initiating with precomplexed PAR2, the protein and competitors, where appropriate, were preincubated without the library and captured on the tip, as described above, followed by three washes of the capture matrix. The library mix was then added to the captured proteinm and then followed by eight additional washes. For selections that included competitors, these were present in all incubations and washes. In all cases, retained library members were eluted by incubation with 60 µL of selection buffer at 72 °C for 5 min, followed by a further incubation with a second 5 µL resin bed of His-Select High-Flow Nickel Affinity Gel to remove any eluted protein. After the first round of selection, the selection protocol was repeated using the library eluted from round 1 for each of the seven conditions. Encoding oligonucleotides present in the output of the second selection round were amplified using Platinum PCR Supermix (Invitrogen, Waltham, MA) with denaturation at 94 °C, annealing at 55 °C, and extension at 72 °C for 24 cycles using 5′ and 3′ primer oligonucleotides (each at 0.5 µM), which each incorporate sequences complementary to the tailpiece or headpiece, along with Illumina READ1 or READ2 sequences, required to support clustering and subsequent single-read 100 base-pair sequencing on an Illumina HiSeq 2500. Sequencing was also performed for PCR-amplified samples of the naïve library for normalization purposes.

Cell Culture

1321N1 cells stably expressing the human PAR2 receptor were cultured in Dulbecco’s modified Eagle’s medium (DMEM) + GlutaMAX supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% pen/strep, 1% G418, and 1% nonessential amino acids. HEK293 cells were cultured in DMEM supplemented with 10% heat-inactivated FBS. To detach cells, PBS containing 1 mM EDTA was used because trypsin-based solutions would cause receptor activation.

Functional Inositol Phosphate Assays

Stimulation of Gαq by PAR2 induced phosphalipase C (PLC) activation and triggered an inositol phosphate (IP) signaling cascade. Inositol-1-phosphate (IP1) is a downstream metabolite of inositol-3-phosphate (IP3), which accumulates in cells following Gαq activation and is stable in the presence of LiCl. Cell-based IP1 assays (Cisbio BioAssys, Codolet, France) were performed in 384-well plates. 1321N1 cells stably expressing the human PAR2 receptor were thawed in media, centrifuged at 1000 rpm for 4 min, and resuspended in preassay buffer (HBSS buffer containing 20 mM HEPES, pH 7.4). In agonist mode, test compound or DMSO controls were prepared in stimulation buffer (HBSS buffer containing 20 mM HEPES, 100 mM LiCl, pH 7.4), serially diluted, and added to wells as required. Subsequently, cells were seeded at a density of 15,000 cells/well into plates and incubated for 30 min at 37 °C, 5% CO₂. Accumulation of IP1 was measured by addition of the IP1-d2 conjugate, followed by the Ab-cryptate according to the manufacturer’s instructions, and incubated at room temperature for 1 h with gentle agitation. Assay plates were read using a PHERAstar homogeneous time-resolved fluorescence (HTRF) cAMP protocol under a time-resolved fluorescence program at 620 and 665 nM. This is a competition-based assay, so that the HTRF ratio is directly inversely proportional to the IP1 concentration. In antagonist mode, test compound or DMSO controls were prepared in preassay buffer, serially diluted as required, and added to the plate. Cells were seeded at a density of 15,000 cells/well into plates and incubated at 37 °C, 5% CO₂. The agonist peptide, SLIGRL, was prepared as a 2 × EC₈₀ concentration (30 µM) in stimulation buffer. After 30 min, the agonist peptide was added to wells to a final assay concentration of 15 µM and cells were incubated for a further 60 min at 37 °C, 5% CO₂.

Results and Discussion

The PAR2 StaR used in affinity-mediated selection experiments has been described previously.⁷ Binding experiments with tool compounds indicated that the PAR2 StaR was in an antagonist-stabilized conformation; the receptor was not able to bind the known agonist GB110.¹² Two preparations of the PAR2 StaR were used in selection: an apo form (a-PAR2), which lacked a bound ligand, and a precomplexed form (pc-PAR2), which was supplied as a complex with the antagonist AZ6343. Previous work had shown that expression and purification in the presence of AZ6343 substantially increased the thermal stability of the purified PAR2 (data not shown). For the selection experiments, pc-PAR2 was captured on the immobilization matrix and then washed to remove AZ6343. During our protein quality control (QC) process, we used MS to determine that both a-PAR2 and pc-PAR2 could bind each of the competitors AZ8838 and AZ7188 following immobilization ( Fig. 2 ).

Figure 2.

(a) Capture efficiency of apo and precomplexed PAR2 StaR on Ni-NTA resin. M = molecular weight marker, I = input, FT = flow-through, E = imidazole elution. (b) Capture efficiency of antagonist AZ8838 by immobilized PAR2 StaR. Antagonist compound was incubated with immobilized receptor, and then washed with fresh buffer. The percent of the total amount of compound captured by the target and the percent lost in the washes were determined by LCMS. Proteins 1 and 2 are negative control targets unrelated to PAR2. (c) Structures of the antagonists AZ6343, AZ8838, and AZ7188, and the agonist GB110.

An affinity-mediated selection campaign was designed to identify library compounds able to bind to PAR2 and to provide competition information with respect to the PAR2 antagonists AZ8838 and AZ7188. This campaign was comprised of seven parallel selection conditions in which a mix of 20 different DECLs were diluted into selection buffer and incubated with no protein (as a negative control) or 5 µM of either a-PAR2 or pc-PAR2. A further variable employed was the presence or absence of AZ8838 or AZ7188. For the selections conducted with a-PAR2, library mix and competitors (when included) were incubated with protein in solution prior to capture. For the selections initiating with pc-PAR2, the protein was captured on the immobilization matrix, followed by washing. The library mix was then added to the immobilized protein. For selections that included competitors, these were present in incubations and washes. In all cases, retained library members were eluted by heat-induced target denaturation at 72 °C. After the first round of selection, the selection protocol was repeated using the library eluted from round 1 for each of the seven conditions. Encoding oligonucleotides present in the output of the second selection round were then amplified, clustered, and sequenced using Illumina/Solexa technology, and each sequence was then translated to identify individual library members. The visualization and analysis of DECL selection outputs have been described previously,^19,23 and were applied to the PAR2 output. Identified families were then profiled for their behavior across the various selection conditions. We find that selection profiles can be conveniently visualized as bar plots,¹⁹ in which each bar represents a selection condition and the height of each bar represents a family’s enrichment under that condition.

Analysis of the output sequence set revealed two families of structurally related compounds whose structures and selection behavior led to their prioritization for further study. The first (family 1) bore a striking structural similarity to GB110 and the native peptide sequence SLIGKV ( Fig. 3 ). Family 1 showed enrichment across both forms of the receptor, and exhibited competitive behavior with both competitors ( Fig. 3b ). Family 1 was discovered within a 225-million-member capped dipeptide library. The most prevalent building blocks at each cycle of family 1 are shown in Figure 3c . Cycles B and C showed completely specific selection, with l-cyclohexylalanine occupying the former and 1-benzyltriazole-4-carboxylate the latter. The cycle A position showed variability among a number of hydrophobic amino acids, with a tetrahydronapthalene derivative (as a mixture of diastereomers) being the most prevalent. The highest-occurring family member had 42 independent occurrences in the 404,799 qualifying sequence reads derived from the selection output for the precomplexed PAR2. This represents an enrichment of 23,000-fold over two rounds of affinity-mediated selection. In comparison with the structure of GB110 and the native peptide, it is apparent that the hydrophobic amino acids at cycle A mimic the isoleucine residue of SLIGKV. The cyclohexylalanine residue occupies the position of the leucine, which is the identical replacement observed in GB110.²⁴ Finally, the triazole moiety overlays well with the isoxazole in GB110; both these heterocycles occupy the position of the N-terminal serine residue. This degree of structural similarity gave us confidence that compound 1 would be a modulator of PAR2 signaling, and indeed it showed agonist activity, with an EC₅₀ value of 230 nM in an inositol monophosphate production assay. This observation was unexpected because the PAR2 StaR had previously been shown to be incapable of binding the agonist GB110 in radioligand displacement assays using receptor loaded into membranes. The selection of the agonist family 1 seems to indicate that the receptor was in equilibrium with an agonist-binding conformation under the conditions of the selection experiment. It is worth noting that family 1 represents the first example of a GPCR agonist discovered by DECL selection.

Figure 3.

(a) Schematic of the capped dipeptide DECL and designations of synthetic cycles A–C. (b) Enrichment profile of family 1 across the various PAR2 selection conditions. (c) Prevalence table for the building blocks comprising family 1. (d) Structure of compound 1 and its response curve in the IP1 agonist assay.

A second cluster of compounds, family 2, was also prioritized ( Fig. 4 ). In contrast to family 1, the second family showed much stronger enrichment with pc-PAR2 than with a-PAR2. Family 2 was also competitive with both added ligands. Structurally, family 2 bore no resemblance to known PAR2 modulators. It was discovered within a 7.1-million-member two-cycle library based on a benzimidazole core. Cycle A showed a marked preference for α-branched cycloalkyl amines ( Fig. 4c ). Cycle B was exclusively 2-halo-4,5-methylenedioxybenzaldehyde, with the bromo analog showing higher prevalence than the chloro one. In the library, the benzimidazole core was attached by either aliphatic or aromatic linkers. Family 2 showed a strong preference for the aromatic linker (data not shown), and so we designed compound 2, in which a phenyl amide was chosen to replace the aromatic linker. Compound 2 had 82 independent occurrences in the 330,309 qualifying sequence reads derived from the selection output for the precomplexed PAR2. This represents an enrichment of 1800-fold over two rounds of affinity-mediated selection. In the inositol monophosphate production assay, compound 2 showed potent antagonistic activity, with an IC₅₀ of 90 nM. Intrigued by the potency of this novel antagonist, we synthesized a number of analogs and characterized them in cellular assays; the data are shown in Figure 4e . Consistent with the linker preference observed in the selection data, truncating the phenylamide to a methylamide (compound 3) resulted in complete loss of observable activity. Also consistent with the selection data, replacement of the bromine with chlorine (compound 4) resulted in a reduction of potency. Replacement of the phenyl linker with a polar cyclic amine (compound 5) yielded an inactive compound. On the other hand, addition of a nitrile group to the phenyl linker gave a slight boost in potency (compound 6, also known as AZ3451).

Figure 4.

(a) Schematic of the benzimidazole DECL and designations of synthetic cycles A and B. (b) Enrichment profile of family 2 across the PAR2 selection conditions. (c) Prevalence table for the building blocks comprising family 2. (d) Response curve of compound 2 in the IP1 antagonist assay. (e) Structures and activities of compound 2 and various analogs.

Compound 6 (AZ3451) was successfully cocrystallized with the PAR2 StaR, and the structure was solved by x-ray diffraction.¹² Interestingly, it binds to an allosteric pocket in the transmembrane region. No overlap with the binding site of AZ8838 (itself an allosteric antagonist) or the predicted orthosteric binding site (of SLIGKV) was seen. This observation was initially surprising in light of the competition seen in selection. The observed competition with AZ8838 and AZ7188 did not indicate a common binding site; instead, it resulted from two sites in allosteric communication, with the binding of one ligand altering the protein fold to prevent the binding of another in a remote pocket. This kind of allosteric communication between sites is likely to be especially common in GPCRs, which require long-range conformational changes to transmit signaling events. For example, the DECL-derived antagonist of the β2 adrenergic receptor was shown to lower the affinity of the agonist isoproterenol by 10-fold.¹¹ The antagonist was subsequently found to bind to the intracellular face of the receptor, distant from the agonist site.²⁵ Unfortunately, ligand competition was not employed in the affinity-mediated selection campaign for β2AR, so we cannot determine whether such allosteric communication would have been identified in the selection profile. Similar situations could also be observed with soluble proteins and enzymes, but we are not aware of any other reports of allosteric competitive behavior in a DECL affinity-mediated selection experiment.

More thorough biophysical characterization of this class of compounds is ongoing, and will be reported in due course. It is interesting to note that in contrast to the family 1 agonists, the family 2 antagonists enriched much more strongly against pc-PAR2 than against a-PAR2. The stronger enrichment with pc-PAR2 would seem to indicate that it retained an antagonist-binding conformation to a greater extent than a-PAR2. Whether this observation is due to the stabilizing effect of the precomplexed ligand or some stabilizing effect of immobilization of the receptor (prior to library incubation) cannot be determined from the available data.

In conclusion, this study illustrates the power of StaRs for affinity-mediated selection of DECLs. Selection using a PAR2 StaR yielded both the first example of a DECL-derived GPCR agonist and a novel series of allosteric antagonists. We suggest that these results indicate that future use of StaRs with DECL technology will be a fruitful approach to the discovery of novel modulators of GPCRs.

Footnotes

Acknowledgements

The authors thank Dr. Daniel Resnicow for his help with preparing this manuscript.

Supplementary material is available online with this article.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors acknowledge AstraZeneca, Heptares, and X-Chem Pharmaceuticals for financial support.

ORCID iD

Stefan Geschwindner

References

Ramachandran

Noorbakhsh

Defea

, et al. Targeting Proteinase-Activated Receptors: Therapeutic Potential and Challenges. Nat. Rev. Drug Discov. 2012, 11, 69–86.

MacFarlane

S. R.

Seatter

M. J.

Kanke

, et al. Proteinase-Activated Receptors. Pharmacol. Rev. 2001, 53, 245–275.

Chackalamannil

Wang

Greenlee

W. J.

, et al. Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity. J. Med. Chem. 2008, 51, 3061–3064.

Suen

J. Y.

Barry

G. D.

Lohman

R. J.

, et al. Modulating Human Proteinase Activated Receptor 2 with a Novel Antagonist (GB88) and Agonist (GB110). Br. J. Pharmacol. 2014, 165, 1413–1423.

Farmer

L. J.

Fournier

P.-A.

Lessard

, et al. Imidazopyridazines Useful as Inhibitors of the PAR-2 Signaling Pathway. WO 2015/048245 A1.

Cheng

R. K. Y.

Fiez-Vandal

Schlenker

, et al. Structural Insight into Allosteric Modulation of Protease-Activated Receptor 2. Nature 2017, 545, 112–115.

Clark

M. A.

Selecting Chemicals: The Emerging Utility of DNA-Encoded Libraries. Curr. Opin. Chem. Biol. 2010, 14, 396–403.

Franzini

R. M.

Neri

Scheuermann

DNA-Encoded Chemical Libraries: Advancing Beyond Conventional Small-Molecule Libraries. Acc. Chem. Res. 2014, 47, 1247–1255.

Arico-Muendel

C. C.

From Haystack to Needle: Finding Value with DNA Encoded Library Technology at GSK. MedChemComm 2016, 7, 1898–1909.

10.

Ahn

Kahsai

A. W.

Biswaranjan

, et al. Allosteric “Beta-Blocker” Isolated from a DNA-Encoded Small Molecule Library. Proc. Natl. Acad. Sci. U.S.A. 2017, 114, 1708–1713.

11.

Graybill

T. L.

Zeng

, et al. Cell-Based Selection Expands the Utility of DNA-Encoded Small-Molecule Library Technology to Cell Surface Drug Targets: Identification of Novel Antagonists of the NK3 Tachykinin Receptor. ACS Comb. Sci. 2015, 17, 722–731.

12.

Robertson

Jazayeri

Errey

, et al. The Properties of Thermostabilized G Protein-Coupled Receptors (StaR^™s) and Their Use in Drug Discovery. Neuropharmacology 2011, 60, 36–44.

13.

Hollenstein

Kean

Bortolato

, et al. Structure of Class B GPCR Corticotropin-Releasing Factor Receptor 1. Nature, 2013, 499, 438–443.

14.

Jazayeri

Rappas

Brown

A. J. H.

, et al. Crystal Structure of the GLP-a Receptor Bound to a Peptide Agonist. Nature 2017, 546, 254–258.

15.

Lebon

Warne

Edwards

P. C.

, et al. Agonist-Bound Adenosine A2A Receptor Structures Reveal Common Features of GPCR Activation. Nature 2011, 474, 521–525.

16.

Christopher

J. A.

Aves

S. J.

Bennett

K. A.

, et al. Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu₅ Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-Fluoropyridin-2-yl)Pyrimidin-4-yl]Benzonitrile). J. Med. Chem. 2015, 58, 6653–6664.

17.

Congreve

Cooke

Fragment Screening of G Protein-Coupled Receptors. In Fragment-Based Drug Discovery; Howard

Abell

C.;

Eds.; Royal Society of Chemistry: London, 2015, pp 101–125.

18.

Cuozzo

J. W.

Centrella

P. A.

Gikunju

, et al. Discovery of a Potent BTK Inhibitor with a Novel Binding Mode Using Parallel Selections with a DNA-Encoded Chemical Library. ChemBioChem 2017, 18, 864–871.

19.

Yang

Medeiros

P. F.

Raha

, et al. Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT). ACS Med. Chem. Lett. 2015, 6, 531–536.

20.

Annis

D. A.

Nazef

Chuang

C.-C.

, et al. A General Technique to Rank Protein-Ligand Binding Affinities and Determine Allosteric versus Direct Binding Site Competition in Compound Mixtures. J. Am. Chem. Soc. 2004, 126, 15495–15503.

21.

Whitehurst

C. E.

Nazef

Annis

D. A.

, et al. Discovery and Characterization of Orthosteric and Allosteric Muscarinic M2 Acetylcholine Receptor Ligands by Affinity Selection–Mass Spectrometry. J. Biomol. Screen. 2006, 11, 194–207.

22.

Clark

M. A.

Acharya

R. A.

Arico-Muendel

C. C.

, et al. Design, Synthesis and Selection of DNA-Encoded Small-Molecule Libraries. Nat. Chem. Biol. 2009, 5 647–645.

23.

Barry

G. D.

Suen

J. Y.

G. T.

, et al. Novel Agonists and Antagonists for Human Protease Activated Receptor 2. J. Med. Chem. 2010, 53, 7428–7440.

24.

Liu

Ahn

Kahsai

A. W.

, et al. Mechanism of Intracellular Allosteric β2AR Antagonist Revealed by X-Ray Crystal Structure. Nature 2017, 548, 480–484.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.46 MB